Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy. See our Privacy Policy and User Agreement for details. Published on Jun 30, SlideShare Explore Search You.

Author:Vihn Daigul
Language:English (Spanish)
Published (Last):26 December 2011
PDF File Size:10.74 Mb
ePub File Size:18.50 Mb
Price:Free* [*Free Regsitration Required]

Carcinomatosis peritoneal de origen colorrectal. Estado actual del tratamiento. Cendoya, I. Magrach, A. Gil, J. Valdovinos e I. Protocolo de tratamiento de Sugarbaker. Desde , el Dr. Este concepto se ha mantenido generalmente aceptado hasta la actualidad. Pocos son los estudios publicados sobre la historia natural de la carcinomatosis de origen colorrectal.

La mediana de supervivencia observada en pacientes afectos de carcinomatosis colorrectal fue de 6 meses para Chu y cols. La supervivencia media en enfermedad localizada fue de 9 meses y de 4 meses cuando la enfermedad estaba generalizada.

Sin embargo no se han conseguido mejoras en la supervivencia Ya en , Sugarbaker y cols. Gilly 58 aporta la primera experiencia en Europa siguiendo la escuela de Fujimoto y Koga 59, Sin embargo Shido y cols.

Como refleja la tabla VI. Glehen y cols. Existen sin lugar a dudas razones para continuar con el tratamiento de las carcinomatosis peritoneales de origen colorrectal. Treatment of primary colon cancer with peritoneal carcinomatosis.

Comparison of concomitant vs. Dis Colon Rectum ; 43 10 : Cir Esp ; 75 3 : Bottomley A. Metastatic colorectal cancer: treatment challenges and quality of life. Lancet ; 4 : Ortiz Hurtado H. Cir Esp ; 1 : 1. Kindler HL, Shulman Kl. Metastatic colorectal cancer. Current Treatment Options in Oncology ; 2: Intraperitoneal chemotherapy for colorectal cancer.

Review article. J Surg Oncol ; Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer. A multi-institutional study of patients. ASCO, ; January: J Clin Oncol ; 22 3 : Sticca RP. Peritoneal carcinomatosis: a final frontier. Ann Surg Oncol ; 10 5 : Extrapelvic colon areas of failure in a reoperation series: implications for adjuvant therapy. Peritoneal seeding following curative resection of colonic carcinoma: implication for adjuvant therapy.

Dis Col Rectum ; Alonso O, Sugarbaker PH. Adult respiratory distress syndrome occurring in two patients undergoing cytoreductive surgery plus perioperative intraperitoneal chemotherapy.

Case reports and a review of the literature. Am Surg ; Sampson JA. Implantation peritoneal carcinomatosis of ovarian origin. Am J Pathol ; 7: Peritoneal carcinomatosis in non-gynecological malignancy: a prospective study of prognostic factors. Cancer ; Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open "coliseum technique".

Ann Surg Oncol ; 7 4 : Nonoperative management of primary colorectal cancer in patients wit stage IV disease. Ann Surg Oncol ; 6 7 : Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from non-gynecological cancer. Ann Surg Oncol ; 8 8 : Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol ; Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer.

Cancer Chemother Pharmacol ; 43 Supl. Pritoneal carcinomatosis from colorectal cancer. Br J Surg ; Antitumor treatment. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treatment Reviws ; Failure patterns following curative resection of colonic carcinoma. Surgery ; 6 : Predictors of short- term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil based regimens.

Am J Clin Oncol ; 25 2 : Anonymous: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced colorectal cancer meta-analysis project. J Clin Oncol ; Anonymous: Efficacy of intravenous continuous infusion of 5-fluorouracil comapared with bolus administration in advanced colorectal cancer: Meta-analysis group in cancer.

Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncology ; 11 2 : Combined irinotecan, oxaliplatin and 5- flourouracil in patients with advanced colorectal caner. A feasibility pilot study. Oncology ; Anonymous: oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5- flourouracil pretreated colorectal cancer.

B J Cancer ; Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. Phase II study of capecitabine and oxaliplatin in first and second line treatment of advanced or metastatic colorectal cancer. J Clin Oncol ; 7: Bliberg H, Hendlisz A. Advanced colorectal cancer treatment in Europe: what have we achieved? Review Paper. Anti-Cancer Drugs ; Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.

Cancer ; 91 7 : Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Xeloda Colorectal Cancer Study Group.

Results of a large phase III study. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer.

A French Intergroup study. Aprospective randomized comparasion of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma.


Hiato de Winslow






Related Articles